AzTrials
AzTrials

Atrial FibrillationAFACARTNCT02113761

Non Invasive Mapping Before Ablation for Atrial Fibrillation.

An observational study of Atrial Fibrillation, run by Brugmann University Hospital at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

RATIONALE / CONTEXT The ECG records the electrical activity propagating along cardiac cells (from the atria to the ventricles). The standard 12 ECG leads placed on the chest measure the global activation of the heart and do not have the ability to detect small-scale disturbances or to pinpoint ectopic activity. Read more about this study

Who is it for?
Ages 15 years and olderHealthy volunteers can take part
Conditions the study is for
Atrial Fibrillation
How many people
100 participants
Where
1 siteBelgium
Study dates
Jan 2014to 21 Dec 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 years and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: Patients with persistent atrial fibrillation as described by the Consensus Statement and with an indication for atrial fibrillation catheter ablation.

Who may be able to join

  • Male or Female Adults (≥18 years old)
  • Minors (15-18 years) of both sexes subject to parental consent or legal representative
  • Persistent AF ablation refractory to drugs
  • Persistent AF (as defined by consensus statement) for ≤ 12 month duration
  • Consent signed by the patient after reading the information leaflet

Who cannot join

  • Any previous left atrial (LA) ablation
  • Any previous LA or RA surgery
  • Current intra-cardiac thrombus
  • Presence of any pulmonary vein stents
  • Presence of any pre-existing pulmonary vein stenosis
  • Anteroposterior LA diameter > 5.5 cm by TTE or CT
Show all 17Show fewer
  • Presence of any cardiac valve prosthesis
  • Clinically significant mitral valve regurgitation or stenosis
  • Myocardial infarction, PCI / PTCA or coronary artery stenting within the last 3 months
  • Unstable angina
  • Any cardiac surgery within the last 3 months
  • NYHA class III or IV congestive heart failure
  • Uncontrolled hyperthyroidism
  • Any cerebral ischemic event (strokes or TIAs) which occurred during the 6 months interval preceding the consent Date.
  • Life expectancy less than one (1) year
  • Current or anticipated participation in any other clinical trial of a drug, device or biologic should be done only after prior consultation and approval of the investigator(s)
  • Unwilling or unable to comply fully with study procedures and follow-up

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • CHU Brugmann

    Brussels, 1020

Other trials in Belgium

About this study

Official title: Non Invasive Mapping Before Ablation for Atrial Fibrillation: the Afacart Study.

RATIONALE / CONTEXT The ECG records the electrical activity propagating along cardiac cells (from the atria to the ventricles). The standard 12 ECG leads placed on the chest measure the global activation of the heart and do not have the ability to detect small-scale disturbances or to pinpoint ectopic activity. By the 1960s, multiple electrodes were placed around the chest to try to understand the complexity of the distribution of electrical activity in relation to the single cardiothoracic geometry of each individual. The safety of this method is similar to the ECG but its superiority has been demonstrated by the detection of anomalies imperceptible to the standard ECG. The accuracy of the technique in localizing rhythm disturbances is on the order of 5 mm.

OBJECTIVES Main objective: To evaluate the utility of noninvasive mapping during persistent AF electrophysiology procedure

Read more

Secondary objectives:

  1. Compare the effectiveness of noninvasive mapping compared to conventional standard of care methods for AF mapping and ablation procedure.
  2. Evaluate the absence of recurrence of persistent AF after a follow up of 12 months after the procedure during a scheduled hospitalization.

DIAGRAM OF RESEARCH European Diagnostic Study, feasibility, non-randomized, multi center

RESEARCH PROCEDURES A trained clinical specialist places 252 dry gelled ECG electrodes on the patient's torso. The 252 ECG electrode array is hooked up to the CardioInsight system and body surface ECG recordings are made during the patient's arrhythmia. The patient is then sent to the radiology department for a CT scan (no contrast) to image both the heart and electrodes on the patient's torso. A trained clinical specialist from CardioInsight then segments the CT DICOM images from the CT scan to obtain epicardial anatomy and establish heart-torso geometry.

The electrograms are processed by the system to produce movies of fibrillatory activity (both focal activity, and rotor activity).

PROCEDURAL ENDPOINTS Primary endpoint: Acute AF termination to atrial tachycardia or sinus rhythm

Secondary outcome criteria:

  • Reduction in RF time compared to standard of care (historical control - comparable patient population)
  • Reduction in procedure time compared to standard of care (historical control - comparable patient population)
  • Freedom from persistent AF at the end of the 12 months F/U period STUDY SIZE

The sample size was estimated at 100 patients, with up to 20 patients per center STUDY CENTERS 8 Centers :

  • Brugmann - Brussels (Belgium)
  • Clinique Pasteur - Toulouse (France)
  • Medizinische Klinik und Poliklinik - Mainz (Germany)
  • University ed Herzzentrum Freiburg Bad Kozingen (Germany)
  • Deutsches Herzzentrum München, Munich (Germany)
  • Kerkhoff Klinik, Bad Nauheim, (Germany)
  • Sint-Jan Sint-Franciscus Xaverius, Brugge (Belgium)
  • Clinique Ambroise Paré, Paris, France

EXPECTED OUTCOME In patients referred for ablation of persistent AF, ECG mapping data will be correlated to the invasive procedure. It is expected that procedure time will be statistically shorter and total RF energy delivery is expected to be smaller than that of standard of care for AF treatment.

Medical subject headings
Atrial Fibrillation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. radiofrequency duration

    Radiofrequency duration necessary to terminate atrial fibrillation and total radiofrequency duration

    Measured: 1 day (At the end of the procedure)

  2. Atrial fibrillation termination

    Amount of patients with AF termination into sinus rhythm or atrial tachycardia during AF ablation.

    Measured: At the time of the procedure of catheter ablation

Secondary outcomes (1)
  1. Atrial fibrillation recurrence

    Measured: One year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Apr 2014 (estimated)
  2. Study startJan 2014
  3. Primary completionJul 2015
  4. Study completion21 Dec 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02113761
Sponsor's protocol ID
BE77201318160
Acronym
AFACART
Status last verified
Feb 2017
First submitted
19 Mar 2014
Last updated
2 Feb 2017
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Atrial Fibrillation, run by Brugmann University Hospital at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

radiofrequency duration (time frame: 1 day (At the end of the procedure)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2017.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
AFACART Clinical Trial NCT02113761 | AzTrials